Novavax, Inc., (NVAX) saw its loss narrow to $57.11 million, or $0.21 a share for the quarter ended Dec. 31, 2016. In the previous year period, the company reported a loss of $78.81 million, or $0.29 a share. Revenue during the quarter dropped 7.76 percent to $5.40 million from $5.85 million in the previous year period.
Operating loss for the quarter was $54.04 million, compared with an operating loss of $78.90 million in the previous year period.
"We've made significant progress executing on the path forward that we outlined in late 2016," said Stanley C. Erck, president and chief executive officer. "For the remainder of the year we will focus on the ongoing Phase 3 trial of our RSV F Vaccine for infants via maternal immunization and on understanding the results of our Phase 2 immunogenicity trial in older adults, along with a deeper understanding of the Resolve Phase 3 trial results we reported last September. We also plan on moving our Zika and nanoparticle influenza vaccine programs into the clinic later this year."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]